Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy

Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy

The efficacy of immunotherapy in advanced HER2‐mutated non‐small‐cell lung cancer (NSCLC) remains incomprehensively studied. A total of 107 NSCLC patients with de novo HER2 mutations were retrospectively studied at Guangdong Lung Cancer Institute [GLCI cohort, exon 20 insertions (ex20ins): 71.0%] to...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Hai‐Yan Tu, Kai Yin, Xiaotian Zhao, E‐E Ke, Si‐Pei Wu, Yang‐Si Li, Mei‐Mei Zheng, Si‐Yang Maggie Liu, Chong‐Rui Xu, Yue‐Li Sun, Jia‐Xin Lin, Xiao‐Yan Bai, Yi‐Chen Zhang, Qing Zhou, Jin‐Ji Yang, Wen‐Zhao Zhong, Bing‐Chao Wang, Xu‐Chao Zhang, Dongqin Zhu, Lingling Yang, Qiuxiang Ou, Yi‐Long Wu
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Wiley 2023-08-01
Saila:Molecular Oncology
Gaiak:
advanced NSCLC
exon 20 insertion
human epidermal growth factor receptor 2
immune checkpoint inhibitor
non‐exon 20 insertion
Sarrera elektronikoa:https://doi.org/10.1002/1878-0261.13439

Internet

https://doi.org/10.1002/1878-0261.13439

Antzeko izenburuak